FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Eval

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Related Keywords

China , Australia , Arvind Dasari , , Global Phase , Clinical Trial Evaluating , Patients With Refractory Metastatic Colorectal , Partnership With , Colorectal Cancer , Refractory Metastatic Colorectal Cancer , Metastatic Colorectal Cancer , Fresco 2 , Fresco 2 Trial , Fresco 2 Study , Fruquintinib , Clinical Trial , Vegf , Overall Survival ,